Global Radiopharmaceuticals In Nuclear Medicine Market Size By Type, By Application, By Geographic Scope And Forecast

Radiopharmaceuticals In Nuclear Medicine Market Size And Forecast

Radiopharmaceuticals In Nuclear Medicine Market size was valued at USD 3.99 Billion in 2020 and is projected to reach USD 6.10 Billion by 2028, growing at a CAGR of 5.47% from 2021 to 2028.

Growing incidences of various cancers, neurological and cardiac disorders have provided an upthrust to the market. In addition, the demand for nuclear medicine is surging owing to target-specific diagnosis and treatment. Nuclear medicine using radiopharmaceuticals has acted as a safer and convenient alternative for the patients which will propel the market growth. The Global Radiopharmaceuticals In Nuclear Medicine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Radiopharmaceuticals In Nuclear Medicine Market Definition

Nuclear medicine refers to medical imaging diagnostics using a radioactively labeled tracer. Radiopharmaceuticals are medicinal formulations comprising radioactively labeled tracers. Radiopharmaceuticals are administered to the patient through intravenous injection before the imaging process. Radiopharmaceuticals are essentially used for detecting and monitoring metabolic disease and its progression in the body. The radioisotopes in the radiopharmaceuticals emit penetrating gamma rays and are detected by single-photon emission computed tomography (SPECT) and positron emission tomography (PET) cameras for diagnosis.

Moreover, these are used for therapeutic purposes. The radioisotopes emit short-range particles and cause local damage in the body for therapeutics. Radiopharmaceuticals are vital to healthcare. They are instrumental in imaging, and in the United States alone, millions of nuclear medicine procedures are performed annually. They are instrumental in the treatment of many malignancies and even many benign tumors. Designing radiopharmaceuticals is a rigorous and complicated process that relies on many different factors. Selecting the appropriate nuclide is critical, as the specific nuclide has a specific half-life and decay mode. These both impact the localization and utility of radiopharmaceuticals. Other factors, such as molecular stability, ease, and production cost, are also important factors.

Global Radiopharmaceuticals In Nuclear Medicine Market Overview

The increasing prevalence of cancer and cardiovascular diseases is contributing to the growth of the market for nuclear medicine and increasing research and development activities by market players are some of the major factors driving the market. Increasing awareness about the potential impact of early diagnosis and corresponding positive impact on the treatment of chronic diseases is expected to drive Radiopharmaceuticals In Nuclear Medicine Market. In addition, technological advancement in nuclear imaging modalities is likely to propel the growth of the market.

Rising demand for nuclear imaging has led to new product launches and the development of a robust diagnostic radiopharmaceutical pipeline is anticipated to boost the market growth. The high prevalence of cancer and wide application of nuclear medicine imaging in its diagnosis further, drive the market. Furthermore Government initiative and funding for the development of new techniques further drive the market growth. Nuclear medicine is also useful in molecular imaging which biomarkers are used to determine the progress of diseases which will propel the market growth during the forecast period. However, the radioisotopes in radiopharmaceuticals have a short half-life and might hamper the market growth.

Global Radiopharmaceuticals In Nuclear Medicine Market: Segmentation Analysis

The Global Radiopharmaceuticals In Nuclear Medicine Market is Segmented based on the basis of Type, Application, and Geography.

Radiopharmaceuticals In Nuclear Medicine Market, By Type

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine

Based on Type, the market is bifurcated into Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine. The diagnostic nuclear medicine segment expected a significant growth during the forecast period owing to the noninvasiveness, cost-effectively, high imaging quality, and wide range of applications in the oncology area. This segment is anticipated to grow at the highest pace due to increasing procedural volume worldwide.

Radiopharmaceuticals In Nuclear Medicine Market, By Application

• Oncology
• Cardiology
• Neurology
• Thyroid
• Others

Based on Application, the market is bifurcated into Oncology, Cardiology, Neurology, Thyroid, and others. The cardiology segment expected significant growth during the forecast period owing to the low cost of techniques and high adoption rate. Therefore, key players are focusing on the development of new diagnostic techniques to combat cardiovascular diseases.

Radiopharmaceuticals In Nuclear Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the Global Radiopharmaceuticals In Nuclear Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America held the dominant share in the market. The rapid adaption of efficient nuclear imaging technologies coupled, with technologically advanced and efficient therapeutics radiopharmaceuticals across the region leads to market growth in this region.

Key Players

The "Global Radiopharmaceuticals In Nuclear Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer, GE Healthcare, Nordion, Novartis AG, Cardinal Health, and Curium. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.